Blockchain Registration Transaction Record

Soligenix Hits Key Milestone in CTCL Treatment Trial with 48% Response Rate

Soligenix completes enrollment for Phase 3 CTCL study with HyBryte showing 48% response rate. Interim analysis scheduled for 2026 in this rare skin cancer treatment trial.

This development represents a significant advancement for patients suffering from cutaneous T-cell lymphoma, a rare and often difficult-to-treat form of skin cancer. The 48% response rate substantially exceeds expectations and suggests HyBryte could become an important new treatment option for a condition with limited therapeutic choices. For the broader pharmaceutical landscape, Soligenix's progress demonstrates the viability of photodynamic therapies for cancer treatment and highlights the importance of continued investment in rare disease research. The successful enrollment milestone also positions the company closer to potential regulatory approval and commercialization, which could provide new hope for CTCL patients worldwide while validating Soligenix's specialized approach to addressing unmet medical needs in rare diseases.